Page last updated: 2024-08-23

pirfenidone and Pulmonary Consumption

pirfenidone has been researched along with Pulmonary Consumption in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Ahidjo, BA; Andrade, BB; Beck, S; Bishai, WR; Cheung, LS; Ihms, EA; Jain, S; Maiga, M; Maiga, MC; Ordonez, AA	1

Other Studies

1 other study(ies) available for pirfenidone and Pulmonary Consumption

Article	Year
The antifibrotic drug pirfenidone promotes pulmonary cavitation and drug resistance in a mouse model of chronic tuberculosis. JCI insight, 2016, 09-08, Volume: 1, Issue:14 Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antitubercular Agents; Drug Resistance, Bacterial; Drug Therapy, Combination; Female; Humans; Isoniazid; Mice; Mice, Inbred C3H; Pyrazinamide; Pyridones; Rifampin; Treatment Outcome; Tuberculosis, Pulmonary	2016

Article

Year

The antifibrotic drug pirfenidone promotes pulmonary cavitation and drug resistance in a mouse model of chronic tuberculosis.

JCI insight, 2016, 09-08, Volume: 1, Issue:14

Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antitubercular Agents; Drug Resistance, Bacterial; Drug Therapy, Combination; Female; Humans; Isoniazid; Mice; Mice, Inbred C3H; Pyrazinamide; Pyridones; Rifampin; Treatment Outcome; Tuberculosis, Pulmonary

2016